Background Human albumin solutions are used for a range of medical and surgical problems. Licensed indications are the emergency treatment of shock and other conditions where restoration of blood volume is urgent, such as in burns and hypoproteinaemia. Human albumin solutions are more expensive than other colloids and crystalloids. Objectives To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in the management of critically ill patients.